EFPIA and EGA unite to propose a way forward in Romania

10 February 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic medicines Association (EGA) said this morning that they fully support the agreement between the pharmaceutical industry associations in Romania to put forward a constructive proposal to the Romanian government that would improve patients’ access to medicines.

The EFPIA and the EGA welcome the agreement between three associations representing pharmaceutical companies in Romania - APMGR, ARPIM and LAWG*- on changes to the clawback system, a realistic medicines budget and the opening of the reimbursement list. If implemented as a holistic package, these changes will foster a more sustainable health care system in Romania.

Measures proposed

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK